Hisamitsu Pharmaceutical Co Inc - ESG Rating & Company Profile powered by AI
The webpage is a free Sustainability analysis for Hisamitsu Pharmaceutical Co Inc. Check the bottom of the webpage for potential risks for Hisamitsu Pharmaceutical Co Inc based on industry, location and marketcap. The analysis of Hisamitsu Pharmaceutical Co Inc uses data from across the web and also from available disclosures by Hisamitsu Pharmaceutical Co Inc.
Hisamitsu Pharmaceutical Co Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.6; made up of an environmental score of 8.0, social score of 8.0 and governance score of 6.7.
7.6
High ImpactEnvironmental
Social
Governance
![Detailed ESG Breakdown](/resource/detailed-esg.png?ts=1737978896147)
Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
140 | Sun Pharmaceutical Industries Ltd | 7.7 | High |
140 | Teva Pharmaceutical Industries Ltd | 7.7 | High |
149 | Hisamitsu Pharmaceutical Co Inc | 7.6 | High |
149 | Alexion Pharmaceuticals Inc | 7.6 | High |
149 | Natco Pharma Ltd | 7.6 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |
![Peer Companies Benchmark](/resource/peer-benchmark-2.png?ts=1737978896147)
Frequently Asked Questions
Does Hisamitsu Pharmaceutical Co Inc have an accelerator or VC vehicle to help deliver innovation?
Does Hisamitsu Pharmaceutical Co Inc disclose current and historical energy intensity?
Does Hisamitsu Pharmaceutical Co Inc report the average age of the workforce?
Does Hisamitsu Pharmaceutical Co Inc reference operational or capital allocation in relation to climate change?
Does Hisamitsu Pharmaceutical Co Inc disclose its ethnicity pay gap?
Does Hisamitsu Pharmaceutical Co Inc disclose cybersecurity risks?
Does Hisamitsu Pharmaceutical Co Inc offer flexible work?
Does Hisamitsu Pharmaceutical Co Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Hisamitsu Pharmaceutical Co Inc disclose the number of employees in R&D functions?
Does Hisamitsu Pharmaceutical Co Inc conduct supply chain audits?
Does Hisamitsu Pharmaceutical Co Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Hisamitsu Pharmaceutical Co Inc conduct 360 degree staff reviews?
Does Hisamitsu Pharmaceutical Co Inc disclose the individual responsible for D&I?
Does Hisamitsu Pharmaceutical Co Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Hisamitsu Pharmaceutical Co Inc disclose current and / or historical scope 2 emissions?
Does Hisamitsu Pharmaceutical Co Inc disclose water use targets?
Does Hisamitsu Pharmaceutical Co Inc have careers partnerships with academic institutions?
Did Hisamitsu Pharmaceutical Co Inc have a product recall in the last two years?
Does Hisamitsu Pharmaceutical Co Inc disclose incidents of discrimination?
Does Hisamitsu Pharmaceutical Co Inc allow for Work Councils/Collective Agreements to be formed?
Has Hisamitsu Pharmaceutical Co Inc issued a profit warning in the past 24 months?
Does Hisamitsu Pharmaceutical Co Inc disclose parental leave metrics?
Does Hisamitsu Pharmaceutical Co Inc disclose climate scenario or pathway analysis?
Does Hisamitsu Pharmaceutical Co Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Hisamitsu Pharmaceutical Co Inc disclose the pay ratio of women to men?
Does Hisamitsu Pharmaceutical Co Inc support suppliers with sustainability related research and development?
Does Hisamitsu Pharmaceutical Co Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Hisamitsu Pharmaceutical Co Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Hisamitsu Pharmaceutical Co Inc involved in embryonic stem cell research?
Does Hisamitsu Pharmaceutical Co Inc disclose GHG and Air Emissions intensity?
Does Hisamitsu Pharmaceutical Co Inc disclose its waste policy?
Does Hisamitsu Pharmaceutical Co Inc report according to TCFD requirements?
Does Hisamitsu Pharmaceutical Co Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Hisamitsu Pharmaceutical Co Inc disclose energy use targets?
Does Hisamitsu Pharmaceutical Co Inc disclose its Renewable Energy targets?
![Only Subscribers](/resource/reload.png)
Are emissions metrics verified by STBi?
![Only Subscribers](/resource/reload.png)
Does Hisamitsu Pharmaceutical Co Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Hisamitsu Pharmaceutical Co Inc
These potential risks are based on the size, segment and geographies of the company.
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, transdermal analgesic anti-inflammatory drug; patches for female hormone, asthma treatment, and treatment for overactive bladders. In addition, the company manufactures and sells drugs under MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Further, it provides HFT-290, a transdermal patch for cancer pain. The company sells its products in the United States and Asia. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.